- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights from the FOURIER Trial2019 | First Faculty of Medicine
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial2019 | First Faculty of Medicine
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial2020 | First Faculty of Medicine
- Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial2018 | First Faculty of Medicine
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial2017 | First Faculty of Medicine
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Treating hypercholesterolaemia with evolocumab +12018 | First Faculty of Medicine